NEWS

March 29, 2021

Karyopharm Receives Conditional Marketing Authorization from the European Commission for NEXPOVIO® (selinexor) in Combination with Dexamethasone for the Treatment of Adult Patients with Relapsed and or Refractory Multiple Myeloma

February 25, 2021

Akebia Announces $60 Million Transaction with HealthCare Royalty

January 6, 2021

HCR Expands Team and Announces Promotions

December 22, 2020

REGENXBIO Announces Agreement to Monetize Portion of Zolgensma^® Royalties for $200 Million

December 22, 2020

Nektar Therapeutics Announces Agreement with Healthcare Royalty to Sell ADYNOVATE^® and MOVANTIK^® Royalties for $150 Million

September 10, 2020

FDA Approves Trelegy Ellipta as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Both Asthma and COPD in the US

August 31, 2020

Chiasma Announces U.S. Commercial Launch and Availability of MYCAPSSA®, the First and Only Oral Somatostatin Analog for Patients with Acromegaly

July 7, 2020

HCR Partners Announces Two New Appointments to Senior Advisor Board

June 26, 2020

Chiasma Announces FDA Approval of MYCAPSSA® (Octreotide) Capsules, the First and Only Oral Somatostatin Analog

June 22, 2020

Karyopharm Announces FDA Approval of XPOVIO® (selinexor) for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)